Amneal Net Debt from 2010 to 2025

AMRX Stock

USD 8.58 0.32 3.87%

Amneal Pharmaceuticals, Net Debt yearly trend continues to be fairly stable with very little volatility. Net Debt will likely drop to about 2.1 B in 2025. Net Debt is the total debt of Amneal Pharmaceuticals, Class minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

2016-12-31

Previous Quarter

2.7 B

Current Value

2.6 B

Quarterly Volatility

842.3 M

Covid

Check Amneal Pharmaceuticals, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amneal Pharmaceuticals,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 154.9 M, Interest Expense of 254.3 M or Selling General Administrative of 281.2 M, as well as many indicators such as Price To Sales Ratio of 0.48, Dividend Yield of 0.096 or PTB Ratio of 50.74. Amneal financial statements analysis is a perfect complement when working with Amneal Pharmaceuticals, Valuation or Volatility modules.

Check out the analysis of Amneal Pharmaceuticals, Correlation against competitors.

Latest Amneal Pharmaceuticals,'s Net Debt Growth Pattern

Below is the plot of the Net Debt of Amneal Pharmaceuticals, Class over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Amneal Pharmaceuticals,'s Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amneal Pharmaceuticals,'s overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

Amneal Net Debt Regression Statistics

	Arithmetic Mean	1,372,860,635
	Coefficient Of Variation	98.17
	Mean Deviation	1,250,489,181
	Median	2,092,546,012
	Standard Deviation	1,347,755,708
	Sample Variance	1816445.4T
	Range	3.1B
	R-Value	0.88
	Mean Square Error	431626.4T
	R-Squared	0.78
	Slope	249,728,744
	Total Sum of Squares	27246681.7T

Amneal Net Debt History

	2025	2.1 B
	2024	3.1 B
	2023	2.7 B
	2022	2.8 B
	2021	2.6 B
	2020	2.6 B
	2019	2.6 B

Other Fundumenentals of Amneal Pharmaceuticals,

Net Debt To E B I T D A

Amneal Pharmaceuticals, Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Good Will	Short Term Investments	Long Term Debt Total	Capital Surpluse	Total Liab	Short Long Term Debt	Total Current Assets	Treasury Stock	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Investments
Total Assets		0.84	-0.95	0.9	-0.35	0.66	0.92	0.85	0.93	-0.79	0.94	0.71	0.94	0.41	0.92	0.31	0.45	0.96	0.81	0.74	0.64	0.96	0.83	0.37	-0.22
Total Stockholder Equity	0.84		-0.83	0.69	0.1	0.82	0.75	0.6	0.68	-0.62	0.77	0.32	0.74	0.01	0.7	-0.01	0.05	0.91	0.5	0.64	0.24	0.81	0.79	0.02	0.01
Net Tangible Assets	-0.95	-0.83		-0.96	0.47	-0.72	-0.97	-0.91	-0.93	0.9	-0.98	-0.73	-0.97	-0.46	-0.94	-0.26	-0.51	-0.98	-0.8	-0.87	-0.7	-0.98	-0.85	-0.33	0.26
Net Debt	0.9	0.69	-0.96		-0.62	0.59	0.99	0.95	0.95	-0.95	0.97	0.85	0.98	0.58	0.97	0.37	0.62	0.91	0.86	0.9	0.75	0.95	0.77	0.45	-0.28
Retained Earnings	-0.35	0.1	0.47	-0.62		-0.02	-0.55	-0.67	-0.58	0.62	-0.52	-0.8	-0.55	-0.81	-0.56	-0.48	-0.83	-0.31	-0.65	-0.55	-0.85	-0.47	-0.23	-0.57	0.49
Accounts Payable	0.66	0.82	-0.72	0.59	-0.02		0.63	0.44	0.48	-0.58	0.63	0.21	0.59	0.07	0.49	0.07	0.1	0.79	0.44	0.67	0.18	0.65	0.52	0.07	-0.11
Long Term Debt	0.92	0.75	-0.97	0.99	-0.55	0.63		0.95	0.95	-0.95	0.99	0.82	0.99	0.54	0.98	0.35	0.57	0.94	0.85	0.92	0.73	0.97	0.82	0.42	-0.29
Net Receivables	0.85	0.6	-0.91	0.95	-0.67	0.44	0.95		0.96	-0.89	0.95	0.91	0.96	0.59	0.97	0.4	0.63	0.85	0.86	0.85	0.85	0.93	0.77	0.48	-0.32
Good Will	0.93	0.68	-0.93	0.95	-0.58	0.48	0.95	0.96		-0.83	0.97	0.9	0.98	0.59	0.98	0.42	0.63	0.89	0.9	0.78	0.8	0.96	0.76	0.51	-0.29
Short Term Investments	-0.79	-0.62	0.9	-0.95	0.62	-0.58	-0.95	-0.89	-0.83		-0.9	-0.75	-0.9	-0.5	-0.89	-0.27	-0.54	-0.84	-0.74	-0.95	-0.7	-0.87	-0.77	-0.34	0.27
Long Term Debt Total	0.94	0.77	-0.98	0.97	-0.52	0.63	0.99	0.95	0.97	-0.9		0.83	1.0	0.53	0.98	0.37	0.57	0.95	0.87	0.88	0.74	0.98	0.81	0.44	-0.27
Capital Surpluse	0.71	0.32	-0.73	0.85	-0.8	0.21	0.82	0.91	0.9	-0.75	0.83		0.86	0.79	0.88	0.65	0.81	0.64	0.92	0.71	0.88	0.78	0.53	0.73	-0.45
Total Liab	0.94	0.74	-0.97	0.98	-0.55	0.59	0.99	0.96	0.98	-0.9	1.0	0.86		0.57	0.99	0.4	0.61	0.94	0.89	0.87	0.76	0.98	0.82	0.48	-0.31
Short Long Term Debt	0.41	0.01	-0.46	0.58	-0.81	0.07	0.54	0.59	0.59	-0.5	0.53	0.79	0.57		0.58	0.76	1.0	0.34	0.79	0.5	0.69	0.52	0.24	0.84	-0.77
Total Current Assets	0.92	0.7	-0.94	0.97	-0.56	0.49	0.98	0.97	0.98	-0.89	0.98	0.88	0.99	0.58		0.42	0.62	0.91	0.89	0.84	0.79	0.97	0.84	0.49	-0.32
Treasury Stock	0.31	-0.01	-0.26	0.37	-0.48	0.07	0.35	0.4	0.42	-0.27	0.37	0.65	0.4	0.76	0.42		0.76	0.23	0.77	0.33	0.51	0.37	0.18	0.99	-0.8
Short Term Debt	0.45	0.05	-0.51	0.62	-0.83	0.1	0.57	0.63	0.63	-0.54	0.57	0.81	0.61	1.0	0.62	0.76		0.38	0.82	0.53	0.73	0.56	0.28	0.84	-0.76
Intangible Assets	0.96	0.91	-0.98	0.91	-0.31	0.79	0.94	0.85	0.89	-0.84	0.95	0.64	0.94	0.34	0.91	0.23	0.38		0.76	0.83	0.59	0.97	0.86	0.29	-0.21
Common Stock	0.81	0.5	-0.8	0.86	-0.65	0.44	0.85	0.86	0.9	-0.74	0.87	0.92	0.89	0.79	0.89	0.77	0.82	0.76		0.75	0.8	0.86	0.62	0.82	-0.61
Property Plant Equipment	0.74	0.64	-0.87	0.9	-0.55	0.67	0.92	0.85	0.78	-0.95	0.88	0.71	0.87	0.5	0.84	0.33	0.53	0.83	0.75		0.62	0.83	0.69	0.38	-0.31
Current Deferred Revenue	0.64	0.24	-0.7	0.75	-0.85	0.18	0.73	0.85	0.8	-0.7	0.74	0.88	0.76	0.69	0.79	0.51	0.73	0.59	0.8	0.62		0.74	0.61	0.6	-0.52
Net Invested Capital	0.96	0.81	-0.98	0.95	-0.47	0.65	0.97	0.93	0.96	-0.87	0.98	0.78	0.98	0.52	0.97	0.37	0.56	0.97	0.86	0.83	0.74		0.88	0.45	-0.36
Net Working Capital	0.83	0.79	-0.85	0.77	-0.23	0.52	0.82	0.77	0.76	-0.77	0.81	0.53	0.82	0.24	0.84	0.18	0.28	0.86	0.62	0.69	0.61	0.88		0.22	-0.29
Capital Stock	0.37	0.02	-0.33	0.45	-0.57	0.07	0.42	0.48	0.51	-0.34	0.44	0.73	0.48	0.84	0.49	0.99	0.84	0.29	0.82	0.38	0.6	0.45	0.22		-0.82
Long Term Investments	-0.22	0.01	0.26	-0.28	0.49	-0.11	-0.29	-0.32	-0.29	0.27	-0.27	-0.45	-0.31	-0.77	-0.32	-0.8	-0.76	-0.21	-0.61	-0.31	-0.52	-0.36	-0.29	-0.82

Click cells to compare fundamentals

About Amneal Pharmaceuticals, Financial Statements

Amneal Pharmaceuticals, investors use historical fundamental indicators, such as Amneal Pharmaceuticals,'s Net Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Amneal Pharmaceuticals,. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Net Debt	3.1 B	2.1 B
Net Debt To EBITDA	5.99	6.29

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

EBR	Centrais Electricas Brasileiras
HE	Hawaiian Electric Industries
VFC	VF Corporation

Additional Tools for Amneal Stock Analysis

When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amneal Net Debt from 2010 to 2025

Latest Amneal Pharmaceuticals,'s Net Debt Growth Pattern

Amneal Net Debt Regression Statistics

Amneal Net Debt History

Other Fundumenentals of Amneal Pharmaceuticals,

Amneal Pharmaceuticals, Net Debt component correlations

About Amneal Pharmaceuticals, Financial Statements

Also Currently Popular

Additional Tools for Amneal Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY